A team of researchers from the Hebrew University of Jerusalem (HU) has completed the first-ever meta-analysis of pediatric patients treated with medical cannabis to understand better the risks and benefits of cannabis use among young patients.
A new joint study conducted by the Ben-Gurion University and Soroka University Medical Centre in Beersheva found that cannabis administered as a treatment for autism spectrum disorders appears to be well-tolerated, and can serve as a safe and effective option to relieve symptoms including seizures, tics, depression, restlessness and rage attacks for patients under the age of 18.
An inter-ministerial committee in Israel has recommended being in favour of exporting medical cannabis after it has gone through medicalisation into a medical product like any other product that patients receive according to labels and dosages and buy it in pharmacies under strict standards.
In a development that could spark Israel’s latest groundbreaking achievement within the medical cannabis sector, the Israeli-British cannabis biotech start-up CIITECH announced Oct. 24 that it will fund a research project in collaboration with the Hebrew University of Jerusalem exploring methods for treating asthma with medical cannabis...writes Adam Abrams/JNS.org.
While international interest in Israel’s groundbreaking medical cannabis sector grows, a leading Israeli player in that space will take its flagship annual event overseas later this month.
